Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Toni K. Choueiri, M.D.

Co-Author

This page shows the publications co-authored by Toni Choueiri and Michelle Hirsch.
Connection Strength

1.803
  1. A case of adult metastatic Xp11 translocation renal cell carcinoma treated successfully with sunitinib. Clin Genitourin Cancer. 2009 Oct; 7(3):E93-4.
    View in: PubMed
    Score: 0.441
  2. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat Commun. 2021 02 05; 12(1):808.
    View in: PubMed
    Score: 0.242
  3. Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. J Clin Oncol. 2020 01 01; 38(1):63-70.
    View in: PubMed
    Score: 0.223
  4. A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies. Cancer. 2016 Aug 01; 122(15):2389-98.
    View in: PubMed
    Score: 0.175
  5. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014 Jun 20; 32(18):1889-94.
    View in: PubMed
    Score: 0.152
  6. Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol. 2013 Jan; 14(1):81-7.
    View in: PubMed
    Score: 0.138
  7. BRAF mutations in metanephric adenoma of the kidney. Eur Urol. 2012 Nov; 62(5):917-22.
    View in: PubMed
    Score: 0.133
  8. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer. 2010 Nov 15; 116(22):5219-25.
    View in: PubMed
    Score: 0.119
  9. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell. 2021 May 10; 39(5):632-648.e8.
    View in: PubMed
    Score: 0.061
  10. Non-clear cell renal cell carcinoma, part 2: therapy. Clin Adv Hematol Oncol. 2015 Jun; 13(6):383-91.
    View in: PubMed
    Score: 0.041
  11. Non-clear cell renal cell carcinoma, part 1: histology. Clin Adv Hematol Oncol. 2015 May; 13(5):308-13.
    View in: PubMed
    Score: 0.041
  12. FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Med. 2014 Aug; 3(4):835-44.
    View in: PubMed
    Score: 0.038
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.